Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 3, randomized, open-label study evaluating DN-101 in combination with docetaxel in androgen-independent prostate cancer (AIPC) (ASCENT-2)

Next Previous
Trial Profile

A phase 3, randomized, open-label study evaluating DN-101 in combination with docetaxel in androgen-independent prostate cancer (AIPC) (ASCENT-2)

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 01 Jul 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Calcitriol (Primary) ; Docetaxel (Primary) ; Dexamethasone; Prednisone
  • Indications Adenocarcinoma; Prostate cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms ASCENT-2
  • Sponsors Transcept Pharmaceuticals Inc

    • Most Recent Events

    • 07 Jun 2022 Results (n=2028) from 4 randomized phase 3 trials (NCT00273338, NCT00988208, NCT00617669, and NCT00519285) presented at the 58th Annual Meeting of the American Society of Clinical Oncology
    • 18 May 2020 Results (n=1577) of Ascent2, Mainsail and Venice trials, inverse correlation between obesity and mortality in patients, presented at the 115th Annual Meeting of the American Urological Association
    • 18 May 2020 Results predicting toxicity related Docetaxel discontinuation using phase III trials presented at the 115th Annual Meeting of the American Urological Association
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top